Table I.
Clinical information of patients with membranous nephropathy and healthy controls.
| A, Patients with membranous nephropathy | ||||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| ID | Sex | Age, years | CR, µmol/l | eGFR, ml/min/1.73 m2 | SBP, mmHg | DBP, mmHg | Pro-24, g/day | Pathological results |
| 160801 | M | 51 | 304.4 | 20.1 | 137 | 69 | 5.55 | MN, stage III |
| 160901 | M | 30 | 68 | 126.2 | 122 | 83 | 4.36 | MN, stage II |
| 161004 | M | 46 | 90 | 83.8 | 112 | 67 | 7.26 | MN, stage II |
| 161005 | F | 43 | 48 | 130.2 | 126 | 72 | 1.92 | MN, stage II |
| 161007 | F | 44 | 61 | 98.2 | 123 | 83 | 3.66 | MN, stage II |
| 170102 | F | 39 | 67 | 90.3 | 122 | 75 | 4.36 | MN, stage II |
| 170103 | M | 53 | 82 | 90.6 | 139 | 82 | 8.90 | MN, stage II |
| 170201 | M | 42 | 93 | 82.2 | 117 | 77 | 2.20 | MN, stage II |
| 170302 | F | 45 | 83 | 68.5 | 139 | 79 | 1.87 | MN, stage I |
| 170402 | M | 50 | 90 | 82.4 | 161 | 100 | 3.63 | MN, stage II |
| 170403 | M | 30 | 95 | 85.8 | 149 | 73 | 7.50 | MN, stage II |
| 170407 | M | 34 | 64 | 132.0 | 113 | 81 | 5.45 | MN, stage II |
| 170502 | M | 44 | 80 | 96.8 | 162 | 106 | 9.33 | MN, stage II |
| 170903 | M | 50 | 220 | 29.4 | 130 | 74 | 6.33 | MN, stage III |
| 180102 | M | 37 | 79 | 101.8 | 119 | 61 | 0.78 | MN, stage II |
| 180304 | F | 43 | 71 | 82.8 | 139 | 81 | 1.80 | MN, stage III |
| 180305 | F | 24 | 64 | 105.1 | 105 | 70 | 2.94 | MN, stage II |
| 180602 | M | 46 | 77 | 100.3 | 137 | 92 | 5.96 | MN, stage II |
| 180702 | M | 44 | 78 | 99.7 | 105 | 56 | 3.26 | MN, stage II |
| 180801 | M | 35 | 88 | 90.9 | 121 | 81 | 2.93 | MN, stage II |
| 180902 | F | 47 | 54 | 111.6 | 135 | 85 | 3.93 | MN, stage I |
| 181003 | M | 44 | 124 | 58.4 | 108 | 73 | 10.36 | MN, stage II |
|
| ||||||||
| B, Healthy controls | ||||||||
|
| ||||||||
| ID | Sex | Age, years | CR, µmol/l | eGFR, ml/min/1.73 m2 | SBP, mmHg | DBP, mmHg | Pro-24, g/day | Pathological results |
|
| ||||||||
| HE1 | M | 40 | 69 | 117.1 | 121 | 56 | 0.04 | Healthy |
| HE2 | M | 55 | 80 | 92.5 | 98 | 73 | 0.03 | Healthy |
| HE3 | M | 34 | 68 | 123.0 | 105 | 79 | 0.10 | Healthy |
| HE4 | M | 33 | 78 | 105.7 | 123 | 55 | 0.034 | Healthy |
| HE5 | M | 42 | 70 | 114.0 | 130 | 85 | 0.06 | Healthy |
| HE6 | M | 34 | 73 | 113.4 | 116 | 79 | 0.05 | Healthy |
| HE7 | M | 40 | 75 | 106.4 | 108 | 88 | 0.08 | Healthy |
| HE8 | M | 45 | 67 | 118.3 | 123 | 72 | 0.12 | Healthy |
| HE9 | M | 50 | 82 | 91.7 | 113 | 59 | 0.09 | Healthy |
| HE10 | M | 43 | 54 | 119.9 | 125 | 86 | 0.08 | Healthy |
| HE11 | F | 58 | 58 | 98.5 | 108 | 84 | 0.10 | Healthy |
| HE12 | F | 43 | 54 | 113.6 | 107 | 76 | 0.08 | Healthy |
| HE13 | F | 38 | 67 | 90.8 | 98 | 82 | 0.12 | Healthy |
| HE14 | F | 34 | 50 | 130.2 | 106 | 75 | 0.03 | Healthy |
| HE15 | F | 42 | 57 | 107.3 | 113 | 83 | 0.04 | Healthy |
Clinical indicators of each patient and healthy controls are listed. Pathological results of patients with membranous nephropathy are also provided. The normal range of CR is 57–97 µmol/l. SBP and DBP were measured before medication therapy. CR, creatinine; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; Pro-24, proteinuria at 24 h; M, male; F, female; MN, membranous nephropathy.